BETHESDA, Md. and GAITHERSBURG, Md.–(BUSINESS WIRE)–A One Health company developing vaccines and diagnostic tools for global public health and zoonotic disease concerns. Longhorn Vaccines and Diagnostics presents new data from two abstracts on LHNVD-110. , the company’s single-peptide universal influenza vaccine candidate, LHNVD-303, and the company’s antimicrobial resistance (AMR) sepsis vaccine candidate, LHNVD-303, were announced at IDWeek 2024. IDWeek will be held in-person from October 16th to 19th, 2024 in Los Angeles, California. .
Despite the development of antibiotics over the past century, AMR continues to pose a threat to patient health and causes millions of deaths worldwide each year. Combating and eradicating AMR will require innovation beyond antibiotics. Longhorn is developing LHNVD-303 as an approach to prevent treatment-resistant strains through a targeted cocktail of lipoteichoic acid, lipopolysaccharide, and peptidoglycan.
Our company will display the following posters.
Poster Title: A single conjugate peptide vaccine containing conserved influenza epitopes formulated with ALFQ adjuvant induced broadly reactive antibodies against human, avian, and swine influenza viruses
Speaker: Clara J. Sei, MPH, Vice President of Vaccine and Antibody Development, Longhorn Vaccines & Diagnostics
Poster Session: Adult Vaccines
Date: October 17, 2024 (Thursday)
Session time: 12:15pm – 1:30pm PST
Session location: Los Angeles Convention Center, Hall JK
Poster title: Development of vaccines and antibodies targeting conserved peptidoglycan, lipoteichoic acid, and lipopolysaccharide epitopes to combat antimicrobial resistance
Speaker: Nimisha Riki, Research Scientist, Longhorn Vaccines & Diagnostics
Poster Session: New Agent
Date: October 18, 2024 (Friday)
Session time: 12:15pm – 1:30pm PST
Session location: Los Angeles Convention Center, Hall JK
IDWeek is a joint annual meeting of the Infectious Diseases Society of America, the American Society for Healthcare Epidemiology, the Society of HIV Medicine, the Pediatric Infectious Diseases Society, and the Society of Infectious Disease Pharmacists.
For more information about Longhorn, please visit www.LHNVD.com.
About Longhorn Vaccines and Diagnosis
Longhorn Vaccines and Diagnostics is a privately held company from Maryland-based One Health that is developing a wide range of vaccines against global public health concerns such as antimicrobial resistance, sepsis, and to prevent future pandemics. We are developing vaccines and diagnostic tools that cover Since its founding in 2006, Longhorn has focused on developing broadly applicable vaccines and diagnostic tools that have the potential to impact pandemics globally and at all socio-economic levels. As pandemics occur between humans and animals, Longhorn products play a critical role in monitoring, diagnosing, preventing and treating the following infectious diseases:
Longhorn’s core product, the PrimeStore® Molecular Transport Media (MTM), is a patented, FDA-cleared, state-of-the-art, ambient temperature molecular diagnostic collection and transport device that is used by governments, the World Health Organization, and pharmaceutical companies. Helps improve diagnosis. Treatment of highly infectious diseases such as influenza, SARS-CoV-2, and Mycobacterium tuberculosis (TB). Unlike standard devices for collecting and transporting viral samples, PrimeStore® MTM is the first molecular delivery device that can safely inactivate pathogens and stabilize RNA and DNA, making it possible to safely inactivate pathogens and stabilize RNA and DNA. Enables enhanced point-of-care and ambient temperature transport for testing and characterization.
contact address
Longhorn Vaccines and Diagnostics LLC
Jeffrey Fisher
Email: jeff@lhnvd.com
media
Alexis Feinberg – ICR Westwick PR
Email: alexis.feinberg@westwicke.com
